BeOne Medicines (BEIGF) Share-based Compensation (2015 - 2026)

BeOne Medicines (BEIGF) has reported Share-based Compensation for 12 consecutive years, with $137.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Share-based Compensation fell 8.89% year-over-year to $137.4 million in Q2 2026; TTM through Jun 2026 was $525.3 million, a 12.11% increase from a year earlier, with the FY2025 full-year figure at $510.9 million, up 15.68% from the prior year.
• Share-based Compensation was $137.4 million for Q2 2026 at BeOne Medicines, up from $123.4 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $150.8 million in Q2 2025 and troughed at $65.6 million in Q1 2022.
• A 5-year average of $104.7 million and a median of $99.7 million in 2023 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation jumped 43.03% in 2022 and fell 8.89% in 2026, its largest moves.
• Over 5 years, Share-based Compensation stood at $78.1 million in 2022, then increased by 18.94% to $92.9 million in 2023, then grew by 15.82% to $107.6 million in 2024, then rose by 15.0% to $123.8 million in 2025, then advanced by 11.02% to $137.4 million in 2026.
• The last three Share-based Compensation figures came in at $137.4 million (Q2 2026), $123.4 million (Q1 2026), and $123.8 million (Q4 2025), per Business Quant data.